# ADA1-Driven Metabolic Refueling Enhances CAR T Cell Therapy for Solid Tumors

## TL;DR

This paper explores how engineering CAR T cells with ADA1 improves their function in solid tumors by converting harmful adenosine into usable inosine, enhancing their survival and effectiveness.

## Contribution

The paper introduces ADA1-driven metabolic reprogramming as a novel strategy to enhance CAR T cell therapy in solid tumors.

## Key findings

- ADA1-expressing CAR T cells show improved survival and antitumor activity in preclinical solid tumor models.
- Conversion of adenosine to inosine by ADA1 reduces T cell exhaustion and enhances metabolic flexibility.
- ADA1-based strategies address key metabolic barriers in the tumor microenvironment.

## Abstract

Solid tumors create a metabolically hostile environment that limits chimeric antigen receptor (CAR) T cell persistence and function, in part through elevated adenosine and restricted nutrient availability. This review focuses on the selective metabolic reprogramming of CAR T cells by adenosine deaminase 1 (ADA1), which converts immunosuppressive adenosine to inosine, providing an alternative fuel and improving cell survival and migration. Engineered expression of ADA1 markedly boosts CAR T cell efficacy in preclinical models by overcoming nutrient competition and suppression, representing a promising direction for next-generation cellular therapies in solid malignancies.

CAR T cell therapy, while highly effective for hematological malignancies, continues to face significant hurdles in the treatment of solid tumors. Key challenges include severe nutrient deprivation and the presence of immunosuppressive metabolites such as adenosine in the tumor microenvironment, which limit CAR T cell persistence and antitumor activity. This review focuses on current progress and future directions for ADA1-based metabolic reprogramming as a targeted approach to enhance CAR T cell function. We discuss recent advances, particularly the engineering of CAR T cells to express ADA1, which facilitates the local conversion of immunosuppressive adenosine into inosine, thereby supporting T cell metabolism and improving therapeutic outcomes. Preclinical studies, including our own, demonstrate that ADA1-expressing CAR T cells exhibit reduced exhaustion, greater metabolic flexibility, and enhanced antitumor efficacy in solid tumor models. The selective clearance of adenosine and supplementation of inosine directly address the metabolic barriers within the tumor microenvironment and provide an effective strategy to bolster CAR T cell responses. Integration of ADA1-driven metabolic refueling with future innovations in CAR design holds promise for overcoming key obstacles in solid tumor immunotherapy. We conclude by highlighting the potential of ADA1-based strategies and offering our perspective on their translation toward clinical application.